

Amendments to the Specification:

Please change the paragraph at page 17, lines 5-32, with the following:

Peptides particularly of interest for use in the present invention include laminin, which has the sequence

YIGSR

(SEQ ID NO: 7)

echistatin, which has the sequence

ECESGPCCRNCFLKEGTICKRARGDDMDDYCNGKTCDCPRNPHKGPAT

(SEQ ID NO: 8)

RGD, NGR and derivatives thereof having the sequences

RX₁ETX₂WX₃

(SEQ ID NO: 9)

wherein X₁, X₂, and X₃ are any amino acid;

CX₁X₂RLDX₃X₄C

(SEQ ID NO: 11)

wherein X₁, X₂, X₃ and X₄ are any amino acid;

~~CXXRGDC~~

~~(SEQ ID NO: 12)~~

X₁X₂X₃RGDX₄X₅X₆

(SEQ ID NO: 13)

wherein X₁, X₃, X₄, and X₆ are capable of forming a bridge (by disulfide bonds, peptide bonds or lactam bonds) and X₂ and X₅ are 1 to 5 amino acids;

CX₂CRGDCX₅C

(SEQ ID NO: 14)

wherein X₂ and X₅ are 1 to 5 amino acids;

X₁X₂DDX₄X₅X₇X₈

(SEQ ID NO: 15)

wherein X₁ and X₈ each is an independently selected amino acid, X₂ and X₇ together equal 0 to 4 amino acids, each amino acid of which is independently selected, X₄ is selected from the group

consisting of glycine and leucine, and X₅ is selected from the group consisting of tryptophan and leucine;

X₁X₂X₃DDX₄X₅X₆X₇X₈

(SEQ ID NO: 16)

wherein X₁ and X₈ each is an independently selected amino acid, X₂ and X₇ together equal 0 to 3 amino acids, each amino acid of which is independently selected, X₃ is selected from the group consisting of tryptophan and proline, X₄ is selected from the group consisting of glycine and leucine, X₅ is selected from the group consisting of tryptophan and leucine, and X₆ is selected from the group consisting of leucine, tryptophan, and methionine.

The substituents X₁, X₂, X₃, X₄, X₅, X₆, X₇, and X₈ are as defined in International applications WO 95/14714, published June 1, 1995 and WO 97/08203, published March 6, 1997 (corresponding to U.S. Pat. Nos. 5,627,263 and 5,817,750, respectively), which are incorporated by reference in their entirety.